Covid-19

#AstraZeneca #Big pharma #Business #Covid-19 #Life sciences #Pfizer

Why investors have their eye on the pharmaceutical sector

Andrew Aldridge, Partner at  Deepbridge Capital explains why life science sector has shot up the UK investment agenda as vaccinations are rolled out. The past twelve months have showcased the importance of medical developments like never before. Innovation in the life sciences sector has been headline news around the globe and… Read More

#Business & Investment #Covid-19 #News #Opinion

#Biopharmaceutical #Covid-19 #Immunology / Virology & Vaccines

Medicago and GSK start Phase III trial of COVID-19 vaccine candidate

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) have begun Phase III clinical testing of Medicago’s plant-derived COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, as part of the ongoing Phase II/III study. Medicago received approval from Canadian and U.S. regulatory authorities to proceed with enrolment… Read More

#Covid-19 #News

#Covid-19 #Drug delivery #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna starts vaccine trials on babies and children

Moderna has announced that the first participants have been dosed in the Phase II/II study, called the KidCOVE study, of mRNA-1273, the company’s vaccine candidate against COVID-19, in children ages 6 months to less than 12 years. The study is being conducted in collaboration with the National Institute of Allergy and… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna doses first patients for its next generation COVID-19 vaccine

Moderna has announced that the first participants have been dosed in the Phase I study of mRNA-1283, the company’s next generation COVID-19 vaccine candidate. mRNA-1283 is being developed as a potential refrigerator stable mRNA vaccine that will facilitate easier distribution and administration by healthcare providers Stéphane Bancel, Chief Executive Officer… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trial #Covid-19 #Immunology / Virology & Vaccines #mRNA

Sanofi and Translate Bio begin clinical trial of COVID-19 vaccine

Sanofi Pasteurand Translate Bio, a clinical-stage mRNA therapeutics company, have announced the start of the Phase I/II clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2. The companies expect interim results from this trial in the third quarter of 2021. Thomas Triomphe, Executive Vice President and Global Head of… Read More

#Covid-19 #News

#Covid-19 #Drug development #Drug discovery #Research study #Study

UK researchers identify inflammatory protein linked to severe COVID-19

Patients with severe COVID-19 show increased levels of a key protein in their blood, which researchers believe may help identify those most at risk. In an analysis of more than 500 COVID-19 patients across the UK, researchers identified several inflammatory markers in blood which increased within the early stages of… Read More

#Covid-19 #News

#AstraZeneca #Covid-19 #Drug development #Immunology / Virology & Vaccines #Moderna #Pfizer

COVID-19 booster shots more likely than vaccines due to variants

Data analytics company, GlobalData says that if new SARS-CoV-2 variants continue to develop, reducing the effectiveness of COVID-19 vaccines and the natural immunity of survivors, then annual booster shots may be required for COVID-19 immunity. Johanna Swanson, Product Manager at GlobalData, said: “Of the several natural variants that have recently been… Read More

#Covid-19 #News

#Biopharmaceutical #Covid-19 #Drug delivery #Immunology / Virology & Vaccines

Novartis and CureVac sign COVID-19 vaccine candidate agreement

Novaratis has signed an initial agreement to manufacture biopharmaceutical company CureVac’s COVID-19 vaccine candidate, CVnCoV. Following final agreement, Novartis plans to start manufacturing of the mRNA and bulk drug product in the second quarter of 2021. It is anticipated to produce up to 50 million doses by the end of… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines

Professor Sarah Gilbert wins award for her work on the Oxford vaccine

The lead researcher on the Oxford vaccine team, Professor Gilbert is Professor of Vaccinology in the Nuffield Department of Medicine at the University of Oxford. She is the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus, SARSCoV-2, with approval for use in many countries around the… Read More

#Covid-19 #Editor's Choice #News #Trending News

#AstraZeneca #Covid-19 #Immunology / Virology & Vaccines #Pfizer #Study

Study shows effectiveness of one dose of COVID-19 vaccine in over 80s

Interim study results show the effectiveness of one dose of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines in preventing hospitalisation of people in their 80s with multiple comorbidities. The AvonCAP study results are by researchers from the University of Bristol, University Hospitals Bristol and Weston NHS Foundation Trust (UHBW) and North Bristol… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines #mRNA

UK government invests £5m into Covid-19 variant vaccines

Budget Chancellor Rishi Sunak announced a £5 million investment in CPI to develop an mRNA ‘vaccine library’, as part of the government’s vaccines support package. The vaccine library will form the basis of a rapid response facility, enabling mRNA vaccines to be developed to help protect against new variants of… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Life sciences

Despite COVID-19, Swedish life science companies in growth mode

A new survey conducted by SwedenBIO shows that Swedish life science companies are more confident about future growth than they were before COVID-19, with 80% planning for new hires and expansion. The survey shows a major upswing in the industry, following on from similar reports a year ago which demonstrated… Read More

#Covid-19 #News

Doctor prepares vaccine
#Covid-19 #Immunodeficiency #Immunology / Virology & Vaccines

New study on vaccine responses for impaired immune systems

A new UK study by Octave seeks to understand the immune response to COVID-19 vaccinations in patients with certain immunosuppressed conditions, including cancer. Funded by the Medical Research Council (MRC), researchers from the Universities of Glasgow, Birmingham (sponsors), Oxford, Liverpool, Imperial College London and Leeds Teaching Hospitals NHS Trust will… Read More

#Covid-19 #News

#Biotherapeutics #Cell culture #Covid-19

Grant given to develop single and multi-organ models for COVID-19 research

CN Bio has received a grant from Innovate UK to develop human-relevant single and multi-organ microphysiological systems (MPS) to advance investigations into SARS-CoV-2 infection and advance 3D lung cell culture models to accelerate drug discovery. The grant will be spent developing and testing advanced cell culture models that represent different… Read More

#Covid-19 #News